オプションチェーンは、Semler Scientificの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Semler Scientificの市場センチメントを評価します。.

Semler Scientific (NASDAQ:SMLR) 株価情報, オプションチェーン

Semler Scientific

Semler Scientific Inc is a United States based company that is engaged in providing technology solutions to improve the clinical effectiveness and efficiency of healthcare providers. It focuses on developing, manufacturing, and marketing proprietary products and services that assist customers, including insurance plans, physicians, and risk assessment groups, in evaluating and treating chronic diseases. The company markets its vascular-testing product under the QuantaFlo brand, which is a four-minute in-office blood flow test.

Semler Scientific Inc

<h3>Gainers</h3>
<ul>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) shares moved upwards by 71.4% to $1.68 during Thursday's pre-market session. The market value of their outstanding shares is at $2.7 million. </li>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) stock rose 55.36% to $0.14. The market value of their outstanding shares is at $14.7 million. </li>
<li>Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) shares rose 28.96% to $19.5. The market value of their outstanding shares is at $137.4 million. </li>
<li>Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) stock rose 27.46% to $75.55. The company's market cap stands at $548.9 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) stock increased by 16.88% to $4.5. The market value of their outstanding shares is at $65.3 million. </li>
<li>DarioHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRIO#NASDAQ">DRIO</a>) stock increased by 14.1% to $0.89. The market value of their outstanding shares is at $30.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Pyxis Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYXS#NASDAQ">PYXS</a>) stock fell 43.5% to $2.16 during Thursday's pre-market session. The company's market cap stands at $128.3 million. </li>
<li>Perspective Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CATX#AMEX">CATX</a>) shares declined by 27.23% to $4.49. The market value of their outstanding shares is at $303.4 million. </li>
<li>Kura Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>) stock decreased by 25.52% to $11.85. The company's market cap stands at $921.5 million. </li>
<li>BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) stock decreased by 22.42% to $0.42. The company's market cap stands at $33.8 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) stock declined by 20.0% to $0.27. The market value of their outstanding shares is at $3.8 million. </li>
<li>Assembly Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASMB#NASDAQ">ASMB</a>) stock fell 11.06% to $13.36. The market value of their outstanding shares is at $84.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ASMB

BDRX

BLRX

CATX

CDTX

DRIO

KURA

PYXS

SLXN

SMLR

WORX

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Alternative online video platform Rumble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUM#NASDAQ">RUM</a>) CEO Chris Pavlovski is considering adding Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) to the company's balance sheet. Here's <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42102652/michael-saylors-microstrategy-takes-wall-street-by-storm-becomes-second-most-traded-stock-after-nvidia">what investors need to know.</a><a href="https://www.benzinga.com/24/11/42079799/microstrategys-michael-saylor-to-advocate-for-bitcoin-investment-at-microsoft-board-meeting-offers-to-educate-rumble-ceo-with-the-strategy"> </a>
The Details: On Tuesday, Pavlovski asked, "Should Rumble add Bitcoin to its balance sheet?" in a post on the social media platform X.&nbsp;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Should Rumble add Bitcoin to its balance sheet?
&mdash; Chris Pavlovski (@chrispavlovski) <a href="https://twitter.com/chrispavlovski/status/1858943901983498298?ref_src=twsrc%5Etfw">November 19, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The post triggered a response from MicroStrategy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) executive chairman and Bitcoin bull Michael Saylor, who offered to discuss with Pavlovski "why and how" the company may want to invest in Bitcoin. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Yes. I would be happy to discuss why &amp; how with you.
&mdash; Michael Saylor&#x26a1;&#xFE0F; (@saylor) <a href="https://twitter.com/saylor/status/1858945523258159169?ref_src=twsrc%5Etfw">November 19, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Pavlovski responded with "DM'ing you now."&nbsp;
Read More: <a href="https://www.benzinga.com/etfs/24/11/42044642/trump-appears-frustrated-as-elon-musk-chimes-in-on-treasury-secretary-adds-more-names-to-a-list-of-potential-picks">Trump Appears &#8216;Frustrated&#8217; As Elon Musk Chimes In On Treasury Secretary, Adds More Names To Short List&nbsp;</a>
Saylor's MicroStrategy has dubbed itself a "Bitcoin Development Company" and currently holds 331,200 Bitcoins, making it the largest institutional holder of the cryptocurrency. MicroStrategy's stock has become a Bitcoin proxy and is up by more than 600% in 2024 and over 100% in the last month alone. 
During a recent X space hosted by asset manager VanEck, Saylor encouraged <a href="https://www.benzinga.com/24/11/42079799/microstrategys-michael-saylor-to-advocate-for-bitcoin-investment-at-microsoft-board-meeting-offers-to-educate-rumble-ceo-with-the-strategy">other companies </a>to hold the cryptocurrency in their reserves.&nbsp;
"I think it's not a bad idea to put it on the agenda of every company. It ought to be put on the agenda of Berkshire Hathaway, Apple, and Google because they all have huge hordes of cash and they're all burning shareholder value," Saylor said
Several companies have <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41683531/michael-saylor-calls-microstrategy-the-public-equity-play-on-bitcoin-maximalism-heres-whos">recently adopted</a> the Bitcoin strategy including Semler Scientific, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) and Metaplanet, Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FNTZF#OTC">FNTZF</a>). Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) will be hosting Saylor to present a case for Bitcoin investment to its board of directors.&nbsp;
Why It Matters: Rumble's Pavloski followed up his original post with a poll asking if Rumble should invest in Bitcoin. 43,790 people responded, and 93.9% of respondents replied, "Yes." 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Lets put this in a poll format&#8230; Should Rumble add Bitcoin to its balance sheet?
&mdash; Chris Pavlovski (@chrispavlovski) <a href="https://twitter.com/chrispavlovski/status/1858977485310025888?ref_src=twsrc%5Etfw">November 19, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Rumble shares rose 9% in after-hours trading Tuesday after Pavlovski posted the Bitcoin investment questions to his social media account. Investors will be watching for further developments from the company.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/41949068/bitcoin-could-reach-1-million-by-2037-economist-says-buy-of-a-lifetime-opportunity">Bitcoin Could Reach $1 Million By 2037, Economist Says: &#8216;Buy Of A Lifetime&#8217; Opportunity</a></li>
</ul>
Image:&nbsp;Liam Ortiz from Pixabay

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

Social Media

General

$BTC

FNTZF

MSFT

MSTR

Rumble CEO Considers Bitcoin Investment, Engages Michael Saylor As Shares Rally

Semler Scientific, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) shares are trading higher Thursday potentially following the company's recent announcement about its Bitcoin (CRYPTO: BTC/USD) activity, capital markets updates and performance indicators. Here&#8217;s <a href="https://www.benzinga.com/quote/SMLR/news">what you need to know.</a>
What To Know: Multiple crypto-linked stocks are moving higher on Thursday after Bitcoin hit <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42109267/bitcoin-hits-new-all-time-high-above-98000-as-spot-etfs-crack-100-billion-net-asset-value-milestone">new all-time highs</a> above $98,000. Some names are outperforming and it appears to be a result of recent Bitcoin accumulation strategies. 
MicroStrategy and MARA Holdings have <a href="https://www.benzinga.com/news/offerings/24/11/42112653/bitcoin-mining-stock-mara-holdings-is-outpacing-peers-whats-going-on">outperformed peers</a> in recent trading sessions. Both companies recently completed offerings and used the proceeds to buy additional Bitcoin as they focus on stockpiling.
Semler Scientific has also adopted a Bitcoin treasury strategy. The company announced it raised $21.5 million through the sale of 505,544 shares of its common stock under an at-the-market offering earlier this week. The proceeds partially funded the company&#8217;s recent Bitcoin purchases.
Semler said it purchased 215 Bitcoin for $17.7 million in cash at an average price of $82,502 between Nov. 6 and Nov. 15. The company now holds a total of 1,273 Bitcoin, acquired for a total cost of $88.7 million.
The rise in Semler's stock price suggests investors are optimistic about the company's strategic use of equity to expand its Bitcoin holdings.
SMLR Price Action: Semler Scientific shares were up 18.9% at $70.50 at the time of publication, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42116475/paying-6-24-million-for-a-duct-taped-banana-justin-sun-did-just-that-and-now-hell-eat-it-as-part-of-this-unique-artistic-experience">Paying $6.24 Million For A Duct-Taped Banana? Justin Sun Did Just That — And Now He&#8217;ll Eat It &#8216;As Part Of This Unique Artistic Experience&#8217;</a></li>
</ul>
Image Via Shutterstock.

Semler Scientific Stock Is Surging Thursday: What's Going On?

U.S. stocks were mixed, with the Nasdaq Composite falling more than 150 points on Thursday.
Shares of BJ&#8217;s Wholesale Club Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>) surged 7% to $91.65 after the company reported better-than-expected third-quarter adjusted EPS results and raised its FY24 adjusted EPS <a href="https://www.benzinga.com/24/11/42111394/bjs-wholesale-stock-soars-after-q3-earnings-beat-outlook-raised">guidance above estimates</a>.
Also, the company approved a new $1 billion share repurchase program.
BJ&#8217;s Wholesale shares surged 7% to $91.65 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) shares jumped 30.9% to $169.05 after the company reported better-than-expected third-quarter financial results and raised its FY25 product revenue guidance. Also, multiple firms raised their respective price targets on the stock.</li>
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) gained 24.2% to $4.5712. Quantum Computing announced it received another purchase order for its photonic chip foundry.</li>
<li>Universal Technical Institute, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UTI#NYSE">UTI</a>) gained 17.7% to $23.41 after the company reported better-than-expected quarterly EPS and sales, and provided FY2024 revenue guidance above analyst estimates..</li>
<li>Semler Scientific, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) shares jumped 17.2% to $69.47.</li>
<li>NANO Nuclear Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) gained 15.1% to $26.63.</li>
<li>MongoDB, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) surged 14.4% to $322.24. MongoDB will report its third quarter fiscal year 2025 financial results for the three months ended Oct. 31, after the U.S. financial markets close on Monday, Dec. 9.</li>
<li>Dream Finders Homes, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFH#NYSE">DFH</a>) gained 14.3% to $31.89 after the company announced it will join the S&amp;P SmallCap 600 and replace Haynes.</li>
<li>Hyliion Holdings Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HYLN#NYSE">HYLN</a>) jumped 12.6% to $3.2750.</li>
<li>Red Cat Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) gained 11.8% to $7.12.</li>
<li>Amentum Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMTM#NYSE">AMTM</a>) jumped 8.1% to $24.24.</li>
<li>Kyndryl Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KD#NYSE">KD</a>) gained 8.1% to $30.85. The company's board authorized a $300 million share repurchase program.</li>
<li>Rubrik, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>) gained 8% to $48.78.</li>
<li>Cloudflare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) gained 6.2% to $102.46.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42112636/top-3-tech-stocks-which-could-rescue-your-portfolio-in-q4">Top 3 Tech Stocks Which Could Rescue Your Portfolio In Q4</a></li>
</ul>

Intraday Update

Markets

Trading Ideas

AMTM

HYLN

QUBT

RBRK

RCAT

SNOW

BJ's Wholesale Club, Snowflake, Universal Technical Institute And Other Big Stocks Moving Higher On Thursday

<a href="https://x.com/saylor/status/1859312952697864218" title="https://x.com/saylor/status/1859312952697864218">https://x.com/saylor/status/1859312952697864218</a> &nbsp;

Watching Semler Scientific; MicroStrategy Chairman Michael Saylor Posts On X "$SMLR is a company on the #Bitcoin Standard."

WIIM

Semler Scientific shares are trading higher after the company announced an increase in BTC and ATM activity and the number of BTC it holds.

U.S. stocks were mixed, with the Dow Jones index falling around 80 points on Monday.
Shares of Twist Bioscience Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) rose sharply during Monday's session after the company reported better-than-expected <a href="https://www.benzinga.com/quote/TWST">fourth-quarter EPS and sales</a>.
Twist Bioscience reported a quarterly loss of 59 cents per share which beat the analyst consensus estimate of a loss of 70 cents per share. The company reported quarterly sales of $84.71 million which beat the analyst consensus estimate of $82.20 million.
Twist Bioscience shares jumped 10.7% to $40.86 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>WeRide Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRD#NASDAQ">WRD</a>) shares gained 19% to $20.67.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) shares surged 19% to $22.12. This surge comes as the company faces potential delisting from the Nasdaq Stock Market.</li>
<li>Amylyx Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) shares climbed 17% to $5.56 after Baird upgraded the stock from Neutral to Outperform and raised its price target from $3 to $11.</li>
<li>REGENXBIO Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>) shares climbed 17% to $11.30 after the company announced dosing the first patient in its pivotal trial for Duchenne gene therapy.</li>
<li>Destiny Tech100 Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXYZ#NASDAQ">DXYZ</a>) shares gained 16.2% to $37.41.</li>
<li>Semler Scientific, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) shares rose 14.6% to $51.00. Semler Scientific announced it acquired 215 bitcoins for $17.7 million in cash, at an average price of $82,502 per bitcoin, inclusive of fees and expenses, during the period between Nov. 6 and Nov. 15.</li>
<li>Red Cat Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) rose 14% to $5.36.</li>
<li>REGENXBIO Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>) gained 13.2% to $10.90 after the company announced dosing the first patient in its pivotal trial for Duchenne gene therapy.</li>
<li>Mobileye Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) rose 8.1% to $16.20.</li>
<li>Zeta Global Holdings Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) shares rose 7.4% to $18.90. Zeta Global said David A. Steinberg, Zeta&#8217;s Co-Founder, Chairman and CEO, members of the Company&#8217;s leadership, and members of the Board of Directors intend to purchase shares of Zeta&#8217;s Class A common stock on Monday.</li>
<li>Aurora Innovation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) gained 7.2% to $5.35.</li>
<li>IAMGOLD Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAG#NYSE">IAG</a>) rose 6.8% to $5.28.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares gained 6.1% to $340.21 following reports of President-elect Donald Trump&#8217;s policy outlook on regulations for autonomous driving.</li>
<li>NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) rose 4% to $4.6650.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42035732/jim-cramer-super-group-basic-materials-stock-is-very-hard-to-own-here">Jim Cramer: Super Group Finally &#8216;Broke Out,&#8217; This Basic Materials Stock Is &#8216;Very Hard To Own Here&#8217;</a></li>
</ul>

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

DXYZ

MBLY

RGNX

SMCI

TSLA

TWST

ZETA

Twist Bioscience Posts Upbeat Results, Joins Tesla, Amylyx Pharmaceuticals, Regenxbio And Other Big Stocks Moving Higher On Monday

Semler Scientific, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>), a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases, today announced updates regarding its bitcoin activity and holdings, capital markets activity, and BTC yield, a key performance indicator that it recently adopted.
BTC Update
Semler Scientific announced that, during the period between November 6, 2024 and November 15, 2024, it acquired 215 bitcoins for $17.7 million in cash, at an average price of $82,502 per bitcoin, inclusive of fees and expenses.
As of November 15, 2024, Semler Scientific held an aggregate of 1,273 bitcoins, which were acquired at an aggregate purchase price of $88.7 million and an average purchase price of $69,682 per bitcoin, inclusive of fees and expenses.
ATM Update
As previously disclosed in Semler Scientific's registration statement on Form S-3 that became effective on August 13, 2024, Semler Scientific entered into a Controlled Equity Offeringsm&nbsp;Sales Agreement (the Sales Agreement) with Cantor Fitzgerald &amp; Co., pursuant to which Semler Scientific may issue and sell from time to time up to $50.0 million of its common stock in an at-the-market (ATM) offering. Since the effective date of the S-3 and as of November 15, 2024, Semler Scientific had sold an aggregate of 505,544 shares under the Sales Agreement for aggregate net proceeds (less sales commissions) of $21.5 million.&nbsp;&nbsp;
BTC Yield as a Key Performance Indicator (KPI)
From October 1, 2024 to November 15, 2024, Semler Scientific's BTC Yield was 18.9%. From July 1, 2024 (the quarter after Semler Scientific adopted its bitcoin treasury strategy) to November 15, 2024, Semler Scientific's BTC Yield was 37.3%.
Semler Scientific uses BTC Yield as a KPI to help assess the performance of its strategy of acquiring bitcoin in a manner Semler Scientific believes is accretive to stockholders. Semler Scientific believes this KPI can be used to supplement an investor's understanding of Semler Scientific's decision to fund the purchase of bitcoin by issuing additional shares of its common stock.

Semler Scientific Announces BTC And ATM Activity Raised $21.5M; Purchased Additional 215 BTC; Now Holds 1,273 BTC With BTC Yield of 37.3%

ERIC SEMLER, Director at Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>), disclosed an insider purchase on November 12, based on a new SEC filing.
What Happened: SEMLER made a significant move by purchasing 50,000 shares of Semler Scientific as reported in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001554859/000110465924116129//Archives/edgar/data/1554859/000110465924116129/0001104659-24-116129-index.htm">U.S. Securities and Exchange Commission</a>. The transaction's total worth stands at $1,896,500.
The latest market snapshot at Tuesday morning reveals Semler Scientific shares down by 0.46%, trading at $51.9.
<h3>All You Need to Know About Semler Scientific</h3>
Semler Scientific Inc is a United States based company that is engaged in providing technology solutions to improve the clinical effectiveness and efficiency of healthcare providers. It focuses on developing, manufacturing, and marketing proprietary products and services that assist customers, including insurance plans, physicians, and risk assessment groups, in evaluating and treating chronic diseases. The company markets its vascular-testing product under the QuantaFlo brand, which is a four-minute in-office blood flow test.
<h3>Unraveling the Financial Story of Semler Scientific</h3>
Revenue Challenges: Semler Scientific's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -17.19%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Exploring Profitability:
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 91.44%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Semler Scientific's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 0.8.
</li>
</ul>
Debt Management: Semler Scientific's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.0.
Analyzing Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 25.47 is lower than the industry average, implying a discounted valuation for Semler Scientific's stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 6.85 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Indicated by a lower-than-industry-average EV/EBITDA ratio of 17.64, the company suggests a potential undervaluation, which might be advantageous for value-focused investors.
</li>
</ul>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Delving Into the Significance of Insider Transactions</h3>
Insider transactions are not the sole determinant of investment choices, but they are a factor worth considering.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Unlocking the Meaning of Transaction Codes</h3>
When dissecting transactions, the focal point for <a href="https://www.benzinga.com/money/investing-tools">investors</a> is often those occurring in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001554859">Check Out The Full List Of Semler Scientific's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Director Of Semler Scientific Purchased $1.90M In Stock

In a new SEC filing on November 12, it was revealed that Murphy-Chutorian, CEO at Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>), executed a significant exercise of company stock options.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001554859/000110465924116136//Archives/edgar/data/1554859/000110465924116136/0001104659-24-116136-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday revealed that Murphy-Chutorian, CEO at Semler Scientific in the Health Care sector, exercised stock options for 100,000 shares of SMLR stock. The exercise price of the options was $2.33 per share.
As of Tuesday morning, Semler Scientific shares are up by 5.76%, with a current price of $55.14. This implies that Murphy-Chutorian's 100,000 shares have a value of $5,281,140.
<h3>Get to Know Semler Scientific Better</h3>
Semler Scientific Inc is a United States based company that is engaged in providing technology solutions to improve the clinical effectiveness and efficiency of healthcare providers. It focuses on developing, manufacturing, and marketing proprietary products and services that assist customers, including insurance plans, physicians, and risk assessment groups, in evaluating and treating chronic diseases. The company markets its vascular-testing product under the QuantaFlo brand, which is a four-minute in-office blood flow test.
<h3>Semler Scientific: Delving into Financials</h3>
Revenue Challenges: Semler Scientific's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -17.19%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Holistic Profitability Examination:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 91.44%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Semler Scientific's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 0.8.
</li>
</ul>
Debt Management: Semler Scientific's debt-to-equity ratio is below the industry average at 0.0, reflecting a lower dependency on debt financing and a more conservative financial approach.
Valuation Overview:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 25.47 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 6.85, Semler Scientific's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio lower than industry averages at 17.64, Semler Scientific could be considered undervalued.
</li>
</ul>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Uncovering the Importance of Insider Activity</h3>
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Unlocking the Meaning of Transaction Codes</h3>
Surveying the realm of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often give prominence to those unfolding in the open market, systematically detailed in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001554859">Check Out The Full List Of Semler Scientific's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options Exercise: Douglas Murphy-Chutorian At Semler Scientific Realizes $5.28M

<h3>Gainers</h3>
<ul>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) shares moved upwards by 147.2% to $0.18 during Tuesday's regular session. The company's market cap stands at $2.9 million. </li>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) shares moved upwards by 143.67% to $0.47. The market value of their outstanding shares is at $6.1 million. </li>
<li>ZyVersa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) shares increased by 35.16% to $2.46. The company's market cap stands at $2.6 million. </li>
<li>Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) shares moved upwards by 29.29% to $38.75. The market value of their outstanding shares is at $270.9 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Inotiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOTV#NASDAQ">NOTV</a>) stock increased by 19.42% to $2.09. The company's market cap stands at $54.3 million. </li>
<li>Athira Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) stock increased by 18.29% to $0.76. The market value of their outstanding shares is at $29.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Verrica Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRCA#NASDAQ">VRCA</a>) shares decreased by 39.9% to $0.86 during Tuesday's regular session. The company's market cap stands at $36.6 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock declined by 29.9% to $1.97. The market value of their outstanding shares is at $3.6 million. </li>
<li>ATI Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATIP#NYSE">ATIP</a>) stock fell 20.49% to $4.09. The market value of their outstanding shares is at $18.0 million. The company's, Q3 earnings came out yesterday. </li>
<li>Bioventus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BVS#NASDAQ">BVS</a>) shares decreased by 19.06% to $11.1. The company's market cap stands at $722.1 million. The company's, Q3 earnings came out today. </li>
<li>Sana Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>) shares decreased by 18.09% to $3.08. The market value of their outstanding shares is at $685.1 million. </li>
<li>LakeShore Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSB#NASDAQ">LSB</a>) stock declined by 15.56% to $1.9. The market value of their outstanding shares is at $36.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATHA

ATIP

BJDX

BNOX

NOTV

NUWE

SANA

VRCA

ZVSA

12 Health Care Stocks Moving In Tuesday's Intraday Session

Semler Scientific shares are trading higher after the company reported better-than-expected Q3 financial results.

Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) reported quarterly earnings of $0.72 per share which beat the analyst consensus estimate of $0.37 by 94.59 percent. This is a 1.41 percent increase over earnings of $0.71 per share from the same period last year. The company reported quarterly sales of $13.512 million which beat the analyst consensus estimate of $13.100 million by 3.15 percent. This is a 17.19 percent decrease over sales of $16.316 million the same period last year.

Earnings

Earnings Beats

Semler Scientific Q3 2024 GAAP EPS $0.72 Beats $0.37 Estimate, Sales $13.512M Beat $13.100M Estimate

Michael Saylor&#8216;s declaration that &#8220;MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) is the public equity play on Bitcoin maximalism&#8221; aptly defines the company&#8217;s pioneering approach in <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41585530/asias-microstrategy-metaplanet-buys-another-10-4m-in-bitcoin-exceeds-1-000-btc-holdings">corporate Bitcoin holdings</a>.
Saylor highlighted the company&#8217;s strategy in a post on X on Thursday:
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">MicroStrategy is the public equity play on <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> Maximalism. <a href="https://t.co/96lpcdN5Zi">pic.twitter.com/96lpcdN5Zi</a>
&mdash; Michael Saylor&#x26a1;&#xFE0F; (@saylor) <a href="https://twitter.com/saylor/status/1852116357724475532?ref_src=twsrc%5Etfw">October 31, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
How MicroStrategy Leverages Bitcoin: MicroStrategy has not only redefined its own treasury strategy but also set a model that other companies are now beginning to emulate.
The firm's Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)-centric approach, producing returns well above the S&amp;P 500, has led to notable shifts in corporate treasury strategies worldwide.
Since MicroStrategy's pivot in 2020, the company has consistently purchased Bitcoin, achieving an annual average return of 44%, significantly higher than the S&amp;P 500&#8217;s 12% <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40776328/microstrategys-bitcoin-strategy-has-outperformed-every-s-p-500-company-and-even-nvidia-sin">during the same period</a>, Saylor told CNBC in a recent interview.
Notably, MicroStrategy's strategy yielded an 825% return, outperforming even Nvidia&#8217;s 821% rise, further showcasing the power of its Bitcoin holdings. 
The firm continues its role as a &#8220;cash cow&#8221; in the software sector while embracing Bitcoin as a primary treasury asset, according to Saylor. 
This dual model allows MicroStrategy to finance Bitcoin acquisitions through securitized instruments like convertible bonds, presenting investors with exposure to Bitcoin at a reduced volatility level.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41667204/what-coin-should-i-buy-binance-founder-changpeng-zhao-shares-anecdotes-from-4-month-prison">&#8216;What Coin Should I Buy?&#8217;—Binance Founder Changpeng Zhao Shares Anecdotes From 4-Month Prison Stint</a>
Who&#8217;s Following The MicroStrategy Apporach: The bold move has stirred interest among other companies, especially as MicroStrategy recently announced its acquisition of 25,889 BTC in Q3, valued at $1.6 billion.
The strategy brought the company's total holdings to 252,220 BTC, worth approximately $18.23 billion, positioning it as a prominent advocate for using Bitcoin as a <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41646462/michael-saylor-says-bitcoin-remedy-to-fix-unhealthy-balance-sheets-as-microstrategy-unveil">hedge in uncertain economic times.</a> 
Despite the risks associated with Bitcoin's volatility, Saylor emphasized that Bitcoin "fixes the balance sheet," offering liquidity and resilience to a firm's finances. 
MicroStrategy plans to raise an additional $42 billion through equity and debt financing in the coming years to further its Bitcoin acquisitions, reinforcing its belief in Bitcoin's long-term value.
Following MicroStrategy's example, companies like Cathedra Bitcoin (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBTTF#OTC">CBTTF</a>), Metaplanet and Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) have implemented similar Bitcoin-centered approaches.
Cathedra Bitcoin, listed on the TSX Venture Exchange, has transitioned its operations from mining to data management to sustainably increase its Bitcoin holdings. 
Meanwhile, Metaplanet has prioritized Bitcoin growth month-over-month, achieving a 587% stock increase this year, reflecting a shift toward maximizing Bitcoin <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40942247/microstrategys-bitcoin-playbook-is-becoming-a-hit-among-companies-but-theres-a-catch">reserves to enhance shareholder value.</a>
This shift, coined the &#8220;<a href="https://www.benzinga.com/startups/24/10/41434521/tesla-quietly-transfers-765-million-in-bitcoin-putting-musks-cryptocurrency-strategy-under-intense-s">maximize Bitcoin per share</a>&#8221; approach, is becoming a compelling alternative for firms seeking inflation hedges and asset stability.
For those interested in the ongoing impact of this strategy on the digital finance landscape, Benzinga's <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19 will be a pivotal platform to explore further, with discussions on corporate adoption and innovations in digital assets expected.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41662414/donald-trump-wishes-bitcoiners-happy-birthday-vows-to-end-kamalas-war-on-crypto-as-world-l">Donald Trump Wishes Bitcoiners &#8216;Happy Birthday&#8217;, Vows To &#8216;End Kamala&#8217;s War On Crypto&#8217; As World Liberty Financial Falls Way Short Of Fundraising Goal</a></li>
</ul>
Image: Shutterstock

CBTTF

Michael Saylor Calls MicroStrategy The 'Public Equity Play On Bitcoin Maximalism': Here's Who's Following This Approach

As Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) becomes a key <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40927528/microstrategy-raises-875m-in-convertible-notes-plans-further-bitcoin-purchases">asset for corporate treasuries</a>, public companies are increasingly adopting innovative strategies to maximize their Bitcoin holdings.
What Happened: What began with MicroStrategy's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) decision to include Bitcoin in its corporate treasury has sparked a wave of similar moves by companies like Cathedra Bitcoin (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBTTF#OTC">CBTTF</a>), Metaplanet and Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>).
The trend is redefining how firms manage their balance sheets and navigate economic uncertainty, <a href="https://www.coindesk.com/business/2024/09/19/maximizing-bitcoin-per-share-a-new-corporate-strategy/?utm_medium=referral&amp;utm_source=rss&amp;utm_campaign=headlines">according</a> to Coindesk.
MicroStrategy, led by Michael Saylor, stands at the forefront of this shift, recently expanding its Bitcoin portfolio to 244,800 coins, valued at nearly $9.45 billion. Saylor's approach, positioning Bitcoin as a hedge against inflation, has sent MicroStrategy's stock soaring—up 295% over the past year. 
The company's continued investments in Bitcoin, including a recent $700 million bond offering to finance more acquisitions, signal a long-term commitment to the cryptocurrency. 
Despite concerns over the stock's mixed technical outlook, Saylor remains bullish, stating that Bitcoin's role in corporate finance will only grow.
MicroStrategy's strategy has paved the way for other companies to follow suit. 
Cathedra Bitcoin, a publicly traded firm on the TSX Venture Exchange, has shifted its focus from Bitcoin mining to managing data centers, aiming to increase its Bitcoin holdings per share. 
As mining becomes more challenging due to Bitcoin halving, Cathedra's new approach allows it to generate sustainable cash flow while continuously acquiring more Bitcoin. 
"Going forward, we will make all capital allocation decisions with the intention of maximizing our shareholders' per-share Bitcoin holdings," the company said in a recent statement.
Metaplanet has taken a similar approach, focusing on growing its Bitcoin reserves month over month. 
The company's strategy has led to a 587% increase in its stock value this year, underscoring the market's positive response to this trend. 
CEO Simon Gerovich emphasized that prioritizing Bitcoin holdings has been a key driver of the company's recent success.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/27091545/Benzinga-conference.gif" alt="Benzinga future of digital assets conference" class="wp-image-267246" /></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40937057/bitcoin-ethereum-etfs-see-over-50m-net-outflows-despite-feds-50-bps-rate-cut">Bitcoin, Ethereum ETFs See Over $50M Net Outflows Despite Fed&#8217;s 50 Bps Rate Cut</a>
Why It Matters: These moves reflect a broader shift toward using Bitcoin not only as a hedge against inflation but as a strategic asset to enhance shareholder value.
Companies like MicroStrategy and Cathedra are now leading the charge in what has been described as the <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40776328/microstrategys-bitcoin-strategy-has-outperformed-every-s-p-500-company-and-even-nvidia-sin">"maximize Bitcoin per share" strategy</a>.
This approach focuses on increasing Bitcoin reserves over time, leveraging the cryptocurrency's long-term growth potential.
MicroStrategy has further diversified its strategy by offering convertible bonds backed by Bitcoin collateral. 
These financial instruments, which offer a 1% interest rate, have attracted investors seeking lower-risk exposure to Bitcoin. 
"We're capturing a 50% premium or 50% type BTC yield on that up front," Saylor said, explaining how the bonds allow the company to acquire more Bitcoin while minimizing volatility.
The success of MicroStrategy's strategy has been hard to ignore. 
Since the company adopted Bitcoin in 2020, it has outperformed every company in the S&amp;P 500, achieving an average annual return of 44%. 
Saylor highlighted that even Nvidia, the index's top-performing stock, has been outpaced by MicroStrategy's Bitcoin-focused approach.
However, the strategy is not without risks. 
With mixed technical signals, including a bearish Moving Average Convergence Divergence (MACD) and a neutral Relative Strength Index (RSI), MicroStrategy's stock could face near-term volatility. 
The company's long-term success will depend on the broader adoption of Bitcoin and the potential for Bitcoin ETFs, which could bring the cryptocurrency <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40899629/microstrategy-doubles-down-on-bitcoin-can-the-stock-sustain-its-rally">further into the financial mainstream.</a>
As Bitcoin continues to reshape corporate strategies, these developments will be a focal point at Benzinga's <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40927528/microstrategy-raises-875m-in-convertible-notes-plans-further-bitcoin-purchases">MicroStrategy Raises $875M In Convertible Notes, Plans Further Bitcoin Purchases</a></li>
</ul>
Image: Shutterstock

MicroStrategy's Bitcoin Playbook Is Becoming A Hit Among Companies, But There's A Catch

A substantial insider activity was disclosed on August 27, as Murphy-Chutorian, CEO at Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>), reported the exercise of a large sell of company stock options.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001554859/000110465924093474//Archives/edgar/data/1554859/000110465924093474/0001104659-24-093474-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday revealed that Murphy-Chutorian, CEO at Semler Scientific in the Health Care sector, exercised stock options for 71,000 shares of SMLR stock. The exercise price of the options was $2.1 per share.
As of Wednesday morning, Semler Scientific shares are down by 1.2%, with a current price of $28.46. This implies that Murphy-Chutorian's 71,000 shares have a value of $1,871,843.
<h3>Get to Know Semler Scientific Better</h3>
Semler Scientific Inc is a United States based company that is engaged in providing technology solutions to improve the clinical effectiveness and efficiency of healthcare providers. It focuses on developing, manufacturing, and marketing proprietary products and services that assist customers, including insurance plans, physicians, and risk assessment groups, in evaluating and treating chronic diseases. The company markets its vascular-testing product under the QuantaFlo brand, which is a four-minute in-office blood flow test.
<h3>Key Indicators: Semler Scientific's Financial Health</h3>
Revenue Challenges: Semler Scientific's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately -22.25%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Key Insights into Profitability Metrics:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 91.32%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Semler Scientific's EPS is below the industry average. The company faced challenges with a current EPS of 0.001584. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: Semler Scientific's debt-to-equity ratio is below the industry average at 0.0, reflecting a lower dependency on debt financing and a more conservative financial approach.
Financial Valuation Breakdown:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 14.19, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 3.63, Semler Scientific's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio of 8.34 trails industry averages, indicating a potential disparity in market valuation that could be advantageous for investors.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Pay Attention to Insider Transactions</h3>
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Essential Transaction Codes Unveiled</h3>
When it comes to transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S indicates a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001554859">Check Out The Full List Of Semler Scientific's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Douglas Murphy-Chutorian At Semler Scientific Capitalizes: Options Exercised, Resulting In $1.87M

Company Sees Growing Institutional Adoption As A Positive Driver For Bitcoin Value And Stockholder Returns

CORRECTION: Semler Scientific Purchases 83 Additional Bitcoins For $5M, Bringing Total Holdings To 1,012 Bitcoins Acquired For $68M

Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) reported quarterly sales of $14.465 million which beat the analyst consensus estimate of $14.200 million by 1.87 percent. This is a 22.25 percent decrease over sales of $18.605 million the same period last year.

Semler Scientific Q2 Sales $14.465M Beat $14.200M Estimate

Semler Scientific's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NYSE">SMLR</a>) short percent of float has risen 123.04% since its last report. The company recently reported that it has 477 thousand shares sold short, which is 8.52% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.32 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Semler Scientific Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1719000920_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Semler Scientific has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Semler Scientific's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Semler Scientific's peer group average for short interest as a percentage of float is 8.55%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Semler Scientific's Recent Short Interest

<h3>Gainers</h3>
<ul>
<li>Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) stock moved upwards by 34.0% to $0.82 during Monday's regular session. The company's market cap stands at $124.5 million. </li>
<li>Renovaro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENB#NASDAQ">RENB</a>) shares increased by 32.51% to $1.71. The market value of their outstanding shares is at $252.1 million. </li>
<li>Champions Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSBR#NASDAQ">CSBR</a>) shares increased by 22.82% to $5.65. The company's market cap stands at $76.8 million. </li>
<li>Nanoviricides (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NNVC#AMEX">NNVC</a>) stock rose 22.02% to $3.26. The market value of their outstanding shares is at $38.4 million. </li>
<li>Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) stock moved upwards by 20.13% to $38.0. The market value of their outstanding shares is at $268.5 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock moved upwards by 18.63% to $1.3. The company's market cap stands at $8.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) stock fell 35.6% to $0.36 during Monday's regular session. The company's market cap stands at $6.8 million. </li>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) stock fell 31.74% to $3.55. The company's market cap stands at $2.7 million. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) stock decreased by 27.83% to $3.65. The company's market cap stands at $1.1 million. </li>
<li>Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) stock fell 19.58% to $7.11. The company's market cap stands at $41.9 million. </li>
<li>Skye Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYE#NASDAQ">SKYE</a>) stock fell 15.0% to $9.3. The market value of their outstanding shares is at $261.0 million. </li>
<li>Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) shares decreased by 14.62% to $15.52. The company's market cap stands at $2.2 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CNSP

CRIS

CSBR

MCRB

NNVC

NVAX

RENB

RNAZ

SBFM

SKYE

THAR

12 Health Care Stocks Moving In Monday's Intraday Session

Shares of Semler Scientific ($SMLR) are little changed today after the medical technology company bought another 83 Bitcoin (BTC-USD) for $5 millio...

Semler Scientific (NASDAQ:SMLR) Buys More Bitcoin, Shares Flat

Semler Scientific ( ($SMLR) ) has issued an update. At Semler Scientific, Inc.'s Annual Meeting, stockholders approved the 2024 Stock Option and In...

Semler Scientific Shareholders Shape Governance and Strategy

Semler Scientific Q3 2024 Earnings Preview

Semler Scientific GAAP EPS of $0.72 beats by $0.35, revenue of $13.5M beats by $0.4M

Semler Scientific, Inc. (SMLR) Q3 2024 Earnings Call Transcript

Semler Scientific ( ($SMLR) ) has released its Q3 earnings. Here is a breakdown of the information Semler Scientific presented to its investors. Se...

Semler Scientific Reports Q3 2024 Earnings and Bitcoin Strategy

Semler Scientific: Topline Challenges Persist, While New Treasury Strategy Prompts A Shift

Bitcoin's Rally: The Tulips Have Done It Again

Semler Scientific (SMLR) announced that, during the period between November 6, 2024 and November 15, 2024, it acquired 215 bitcoins for $17.7 milli...

Semler Scientific provides update on recent BTC, ATM activity

Semler Scientific buys additional 215 bitcoins

FBTC

GBTC

IBIT

Press Releases

Semler Scientific® Reports First Quarter 2024 Financial Results

Semler Scientific® Announces Bitcoin Treasury Strategy

Semler Scientific® Announces Additional Bitcoin Purchases

Semler Scientific to Report Second Quarter and First Half of 2024 Financial Results and Host Conference Call on August 5, 2024

Semler Scientific® Reports Second Quarter 2024 Financial Results and Additional Bitcoin Purchases

Fintech

Semler Scientific Announces Additional Bitcoin Purchases

Kaskela Law LLC Announces Shareholder Investigation of Semler Scientific, Inc. (NASDAQ: SMLR) and Encourages Investors to Contact the Firm

Semler Scientific to Report Third Quarter and First Nine Months of 2024 Financial Results, Provide an Update on Bitcoin Holdings and Host Conference Call on November 4, 2024

Small Cap

Semler Scientific® Reports Third Quarter 2024 Financial Results and Additional Bitcoin Purchases

Semler Scientific® Announces BTC and ATM Activity Raised $21.5 million; Purchased Additional 215 BTC; Now Holds 1,273 BTC with BTC Yield of 37.3%

Comments

Semler Scientific

Semler Scientific (SMLR) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル